RxAnte, Inc., headquartered in the United States, is a leading innovator in the healthcare technology sector, specialising in medication management and optimisation solutions. Founded in 2013, the company has made significant strides in improving patient outcomes through its advanced analytics and predictive modelling capabilities. With a focus on enhancing medication adherence and reducing healthcare costs, RxAnte offers unique services that leverage data-driven insights to support healthcare providers and payers. Their core products, including the RxAnte Platform, empower organisations to identify at-risk patients and tailor interventions effectively. Recognised for its commitment to transforming medication management, RxAnte has established a strong market position, serving a diverse range of clients across the healthcare landscape. The company continues to drive advancements in the industry, making a meaningful impact on patient care and operational efficiency.
How does RxAnte, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
RxAnte, Inc.'s score of 23 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
RxAnte, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that RxAnte may not have established formal commitments to reduce its carbon footprint or may be in the early stages of developing such initiatives. In the context of the industry, many organisations are increasingly adopting science-based targets and sustainability commitments to address climate change. However, without specific emissions data or reduction initiatives, it is unclear how RxAnte aligns with these industry standards. As the company progresses, it may consider implementing strategies to measure and reduce its carbon emissions, thereby contributing to broader climate action efforts.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
RxAnte, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
